Early Treatment with Pegylated Interferon Lambda for Covid-19
Gilmar Reis, Eduardo A S Moreira Silva, Daniela C Medeiros Silva, Lehana Thabane, Vitoria H S Campos, Thiago S Ferreira, Castilho V Q Santos, Ana M R Nogueira, Ana P F G Almeida, Leonardo C M Savassi, Adhemar D Figueiredo-Neto, Ana C F Dias, Adelino M Freire Júnior, Carina Bitarães, Aline C Milagres, Eduardo D Callegari, Maria I C Simplicio, Luciene B Ribeiro, Rosemary Oliveira, Ofir Harari, Lindsay A Wilson, Jamie I Forrest, Hinda Ruton, Sheila Sprague, Paula Mckay, Christina M Guo, Eve H Limbrick-Oldfield, Steve Kanters, Gordon H Guyatt, Craig R Rayner, Christopher Kandel, Mia J Biondi, Robert Kozak, Bettina Hansen, M Atif Zahoor, Paul Arora, Colin Hislop, Ingrid Choong, Jordan J Feld, Edward J Mills, Jeffrey S Glenn
New England Journal of Medicine, doi:10.1056/nejmoa2209760
BACKGROUND The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear.
METHODS We conducted a randomized, controlled, adaptive platform trial involving predominantly vaccinated adults with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brazil and Canada. Outpatients who presented with an acute clinical condition consistent with Covid-19 within 7 days after the onset of symptoms received either pegylated interferon lambda (single subcutaneous injection, 180 μg) or placebo (single injection or oral). The primary composite outcome was hospitalization (or transfer to a tertiary hospital) or an emergency department visit (observation for >6 hours) due to Covid-19 within 28 days after randomization.
RESULTS A total of 933 patients were assigned to receive pegylated interferon lambda (2 were subsequently excluded owing to protocol deviations) and 1018 were assigned to receive placebo. Overall, 83% of the patients had been vaccinated, and during the trial, multiple SARS-CoV-2 variants had emerged. A total of 25 of 931 patients (2.7%) in the interferon group had a primary-outcome event, as compared with 57 of 1018 (5.6%) in the placebo group, a difference of 51% (relative risk, 0.49; 95% Bayesian credible interval, 0.30 to 0.76; posterior probability of superiority to placebo, >99.9%). Results were generally consistent in analyses of secondary outcomes, including time to hospitalization for Covid-19 (hazard ratio, 0.57; 95% Bayesian credible interval, 0.33 to 0.95) and Covid-19-related hospitalization or death (hazard ratio, 0.59; 95% Bayesian credible interval, 0.35 to 0.97). The effects were consistent across dominant variants and independent of vaccination status. Among patients with a high viral load at baseline, those who received pegylated interferon lambda had lower viral loads by day 7 than those who received placebo. The incidence of adverse events was similar in the two groups.
CONCLUSIONS Among predominantly vaccinated outpatients with Covid-19, the incidence of hospitalization or an emergency department visit (observation for >6 hours) was significantly lower among those who received a single dose of pegylated interferon lambda than among those who received placebo. (Funded by FastGrants and others; TOGETHER ClinicalTrials.gov number, NCT04727424.
References
Andreakos, Salagianni, Galani, Koltsida, Interferon-λs: front-line guardians of immunity and homeostasis in the respiratory tract, Front Immunol
Banday, Stanifer, Florez-Vargas, Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries, Nat Genet
Baños-Lara, Harvey, Mendoza, Impact and regulation of lambda interferon response in human metapneumovirus infection, J Virol
Chan, Ahn, Chang, Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B), J Hepatol
Davidson, Mccabe, Crotta, IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment, EMBO Mol Med
Dinnon, Iii, Leist, Schäfer, A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures, Nature
Dodd, Freidlin, Korn, Platform trials -beware the noncomparable control group, N Engl J Med
Feld, Kandel, Biondi, Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial, Lancet Respir Med
Hakim, Chen, Ding, Basal interferon signaling and therapeutic use of interferons in controlling rotavirus infection in human intestinal cells and organoids, Sci Rep
Jagannathan, Andrews, Bonilla, Peginterferon lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial, Nat Commun
Montori, Permanyer-Miralda, Ferreira-González, Validity of composite end points in clinical trials, BMJ
Muir, Arora, Everson, A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection, J Hepatol
Nice, Baldridge, Mccune, Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity, Science
Orkin, Gill, Ghersi, Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement, JAMA
Prokunina-Olsson, Dickenson, COVID-19 and emerging viral infections: the case for interferon lambda, J Exp Med
Reis, Silva, Silva, A multicenter, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and highrisk for complications: the TOGETHER master trial protocol, Gates Open Research
Schandelmaier, Briel, Varadhan, Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses, CMAJ
Schulz, Altman, Moher, WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research, Lancet Infect Dis
